AbbVie Inc vs Modine Manufacturing Company — how do they compare? AbbVie Inc trades at $248.81 (market cap $438.19B), while Modine Manufacturing Company trades at $200.79 (market cap $10.15B). The key difference: AbbVie Inc is far larger — about 43.2× Modine Manufacturing Company's market cap, and AbbVie Inc pays a 2.79% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals.
| ABBV | MOD | |
|---|---|---|
Market Cap | $438.19B | $10.15B |
Sector | Health | Technology |
52-Week High | $263.58 | $306.89 |
52-Week Low | $197.38 | $119.68 |
Enterprise Value | $502.45B | $10.58B |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.19, up 1.28% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust immunology drug performance from Skyrizi and Rinvoq are offsetting Humira patent losses, driving revenue growth to $61.16B in 2025. The stock is near its pivot point of $247, with support at $245 and resistance at $249.
The outlook remains positive with a consensus price target of $281.33, though high P/E of 70.05 and looming patent cliffs in the 2030s present risks. Dividend growth and institutional accumulation support the buy case, but margin compression and debt levels warrant monitoring.
Modine Manufacturing (MOD) trades at $195.60, up 1.6% on the day, with a bearish technical signal but strong fundamental growth driven by data center demand. The stock shows stretched valuation with a P/E of 71.27, yet has beaten earnings estimates for three consecutive quarters. Recent news highlights surging data center sales but also margin pressure and supply-chain constraints.
Outlook is mixed: robust revenue growth and a $319 consensus price target suggest upside, but high valuation, margin compression, and technical weakness pose risks. Investors should weigh strong analyst buy ratings against execution challenges in a competitive thermal management market.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →